Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Core Points - Incannex Healthcare Inc. has received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price requirement, allowing until April 20, 2026, to maintain a closing bid price of at least US$1.00 per share for a minimum of ten consecutive business days [1][2] - The extension was granted as Incannex continues to meet all other continued listing criteria for the Nasdaq Capital Market and has indicated its intention to cure the deficiency, potentially through a reverse stock split [2][3] - The company has successfully delivered two Phase 2 clinical data packages this year, validating its development platform and positioning it for future growth [3] Company Overview - Incannex Healthcare is focused on developing combination medicines targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [4] - The lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide aimed at treating obstructive sleep apnea [4] - IHL-675A, another clinical-stage product, combines cannabidiol and hydroxychloroquine sulfate to alleviate inflammatory conditions like rheumatoid arthritis, while PSX-001 is an oral synthetic psilocybin treatment for generalized anxiety disorder [4]